When promising early-stage data doesn't translate to late-stage success, it hurts. Ultragenyx Pharmaceutical Inc. (RARE) and its partner Mereo BioPharma Group plc (MREO) learned that lesson the hard way Monday, watching their stocks crater to 52-week lows after their experimental bone disorder treatment flopped in pivotal trials.

The two companies announced results from their Phase 3 Orbit and Cosmic studies evaluating setrusumab (UX143) as a treatment for Osteogenesis Imperfecta. If you're not familiar, Osteogenesis Imperfecta is a group of genetic disorders affecting bone metabolism. Collagen mutations make bones dangerously brittle, leading to frequent fractures.

The verdict? Neither study hit its primary endpoint. Setrusumab failed to significantly reduce the annualized clinical fracture rate compared to placebo in one trial or bisphosphonates in the other. That's the outcome that mattered most, and it simply didn't happen.

Here's the puzzling part: both studies showed that setrusumab achieved secondary endpoints, delivering improvements in bone mineral density compared to the control groups. The safety profile remained unchanged, with no new concerns emerging. So the drug made bones denser, but didn't prevent fractures at a statistically meaningful level.

"We are surprised and disappointed by these results given the promising data from our Phase 2 study," said Emil Kakkis, chief executive officer and president of Ultragenyx. "We continue to explore the data to gain a deeper understanding of the findings."

What Went Wrong in the Two Studies

The Orbit study delivered a head-scratcher. Participants saw statistically significant improvements in bone mineral density compared to placebo, matching the treatment effect from the earlier Phase 2 portion. But those BMD gains didn't translate into fewer fractures. Making matters more complicated, the placebo group had an unexpectedly low fracture rate, which might have made it harder to show a benefit.

The pediatric Cosmic study painted a slightly different picture. These younger patients started with substantially higher baseline fracture rates than the Orbit participants. In this population, the meaningful BMD improvements did correlate with a reduction in annualized fracture rates for setrusumab-treated patients compared to those on bisphosphonates. The problem? The reduction didn't cross the threshold for statistical significance.

Ultragenyx is now digging deeper into the data from both studies, examining other bone health and clinical endpoints beyond fractures to figure out what comes next for the program.

The company also isn't sugarcoating the financial implications. Ultragenyx said it's evaluating operations and will implement significant expense reductions.

Despite the setback, Kakkis tried to emphasize the bigger picture: "While we are disappointed by these results, we continue to build our commercial revenue from four approved products and prepare for a transformational year ahead with potentially two near-term gene therapy launches and a pivotal Phase 3 readout in Angelman syndrome."

Price Action: Ultragenyx Pharmaceutical shares tumbled 43.96% to $19.16, hitting a new 52-week low. Mereo BioPharma fared even worse, plunging 89.32%.